Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Genor Biopharma Holdings's PEG Ratio or its related term are showing as below:
FRA:67N0'
s PEG Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.48
Current: 0.48
During the past 7 years, Genor Biopharma Holdings's highest PEG Ratio was 0.48. The lowest was 0.00. And the median was 0.00.
FRA:67N0's PEG Ratio is not ranked
in the Biotechnology industry.
Industry Median: 1.925
vs FRA:67N0: 0.48
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Genor Biopharma Holdings (FRA:67N0) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Genor Biopharma Holdings PEG Ratio Related Terms
Genor Biopharma Holdings PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:67N0 vs VRTX, REGN, ALNY: PEG Ratio Comparison
For the Biotechnology subindustry, Genor Biopharma Holdings's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genor Biopharma Holdings PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Genor Biopharma Holdings's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Genor Biopharma Holdings (FRA:67N0) has a PEG Ratio of 0.48 as of Jul. 14, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Genor Biopharma Holdings and its competitors.
Is Genor Biopharma Holdings' PEG Ratio too high?
Genor Biopharma Holdings' current PEG Ratio is 0.48. The Biotechnology industry median PEG Ratio is 1.93. Genor Biopharma Holdings' value of 0.48 is 75.1% below this industry median. Overall, Genor Biopharma Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Genor Biopharma Holdings' PEG Ratio compare to VRTX and REGN?
Genor Biopharma Holdings' PEG Ratio of 0.48 can be compared against companies in the Biotechnology industry. The industry median PEG Ratio is 1.93. Genor Biopharma Holdings' value of 0.48 is 75.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.93, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genor Biopharma Holdings's current PEG Ratio of 0.48 is 75.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Genor Biopharma Holdings and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genor Biopharma Holdings's current PEG Ratio is 0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genor Biopharma Holdings stock overvalued right now?
Genor Biopharma Holdings (FRA:67N0) has a current PEG Ratio of 0.48. The current PEG Ratio is 0.48 and 75.1% below the Biotechnology industry median of 1.93. Genor Biopharma Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Genor Biopharma Holdings (FRA:67N0), the current PEG Ratio is 0.48 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
22GF Score
Get the complete analysis for FRA:67N0
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:67N0 has been successfully added to your 
